Pfizer Drops Cardiology Drug after Phase 3 Trials Failed


Pfizer is dropping one of the assets it picked up in the takeover of Array Bio Pharma, worth 11.4 billion dollars three years ago. After carrying out a phase 3 interim futility analysis, Big Pharma has decided to stop working on the cardiovascular disease candidate PF-07265803.

With Array BioPharma kicking it off in 2018, Pfizer has also embraced the program, which hails the work of PF-07265803 for the dilated cardiomyopathy with lamin A/C gene mutation as part of the growing leadership of Pfizer in rare cardiology.

Because the condition is associated with activation of the p38 MAPK kinase, and Pfizer bet that inhibiting the pathway can improve the performance on the walk test of six-minute. The hypothesis failed to survive an interim futility analysis, and Pfizer is also stopping the study, and further development of PF-07265803.

This blow comes following delays to the trial that caused its targeted initial completion date to slip from 2023 to 2024, and the company also increased the enrolment target from 160 to 200 in March 2022.

See also  UK Government to Consider New Approach to Prevent Severe Cardiovascular Disease

The failure to translate the effects into humans is a blow for the patients with dilated cardiomyopathy related to LMNA, 70 percent of whom have cardiac death, which is a heart transplant.


Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.

I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.

I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!